Distribuito in ITALIA da
Li StarFish S.r.l.
Via Cavour, 35
20063 Cernusco S/N (MI)
telefono 02-92150794
info@listarfish.it
www.listarfish.it

Manual

Nitrotyrosine ELISA

For the in vitro determination of nitrotyrosine in human EDTA plasma, serum and dried blood spots

Valid from 2019-05-02

K 7829

96



REF **K 7829.20**



20 x 96

Immundiagnostik AG, Stubenwald-Allee 8a, 64625 Bensheim, Germany
Tel.: +49 6251 70190-0 Fax: + 49 6251 70190-363
e.mail: info@immundiagnostik.com www.immundiagnostik.com

Table of Contents

1. INTENDED USE

This Immundiagnostik AG assay is an enzyme immunoassay intended for the quantitative determination of protein-bound nitrotyrosine in human EDTA plasma, serum and dried blood spots. For *in vitro* diagnostic use only.

2. INTRODUCTION / CLINICAL RELEVANCE

Nitrotyrosine is the nitrated form of the amino acid tyrosine. The accumulation of protein bound nitrotyrosine is associated with cardiovascular diseases that are based on inflammatory processes (e.g., atherosclerosis, myocardial infarction, diabetic vasculopathy, hypertension, or coronary heart diseases). A growing number of studies have also associated the accumulation of nitrotyrosine with neurological diseases (Alzheimer´s disease, Parkinson´s disease, multiple sclerosis, stroke).

With treatment of some of the associated diseases the levels of nitrated tyrosines have been shown to decrease, so nitrotyrosine has been stated to be a marker of nitrosative stress. During inflammatory processes, large amounts of nitric oxide (•NO) are locally released from L-arginine. This reaction is catalysed by the enzyme NO-synthase (NOS). Other causes for the increased •NO production are exposure to chemicals or heavy metals, drugs, nicotine, or physical and psychological stress, as well as extraordinary physical strain with increased oxygen consumption. In high concentrations, •NO that is not trapped by mitochondrial superoxide dismutase (MnSOD) reacts with superoxide ($•OO^-$) to form peroxynitrite. ($ONOO^-$). Peroxynitrite is implicated as a key oxidant species in several pathologies and is known to be cytotoxic (nitrosative stress). Peroxinitrite is highly reactive and shows a high affinity to aromatic amino acids, e.g., to the phenolic ring of tyrosine. The nitration of tyrosine in general is a natural process within the post-translational protein modification. Nitrotyrosine is a stable product and might be seen as a correlate of peroxynitrite production, and its accumulation in cells and tissues is a marker of oxidative stress and nitrosative stress, respectively.

Indications

- Cardiovascular diseases
- Neurological diseases
- Thyroid disturbances
- Blockade of biochemical pathways
- Mitochondriopathy

Consequences of nitrosative stress

- Modification of lipids and proteins (for example structural proteins in mitochondria)

- Inhibition of respiratory chain enzymes in the mitochondria
- Glutamate overload
- Disturbances in ion channels
- Calcium overload
- Initiation of apoptosis processes

3. MATERIAL SUPPLIED

Cat. No.	Label	Kit components	Quantity for cat. no.	
			K 7829	K 7829.20
K 7829	PLATE	Microtiter plate, pre-coated	12 x 8 wells	20 x 12 x 8 wells
K 0001.C.100	WASHBUF	Wash buffer concentrate, 10x	1 x 100 ml	20 x 100 ml
K 7829	ASYBUF	Assay buffer, ready-to-use	1 x 100 ml	20 x 100 ml
K 7829	CONJ	Conjugate concentrate (goat anti-human-serum proteins, peroxidase-labelled)	1 x 200 µl	20 x 200 µl
K 7829	STD	Standards, lyophilised (see specification for concentration)	2 x 6 vials	25 x 6 vials
K 7829	CTRL1	Control, lyophilised (see specification for range)	2 x 1 vial	25 x 1 vial
K 7829	CTRL2	Control, lyophilised (see specification for range)	2 x 1 vial	25 x 1 vial
K 0002.15	SUB	Substrate (tetramethyl-benzidine), ready-to-use	1 x 15 ml	20 x 15 ml
K 0003.15	STOP	Stop solution, ready-to-use	1 x 15 ml	20 x 15 ml

For reorders of single components, use the catalogue number followed by the label as product number.

4. MATERIAL REQUIRED BUT NOT SUPPLIED

- Ultrapure water*
- Dried blood spot carrier such as DrySpot-ID cat. no.: DZ9020ID or DZ9021ID
- Calibrated precision pipettors and 10–1000 µl single-use tips
- Foil to cover the microtiter plate
- Horizontal microtiter plate shaker
- Multi-channel pipets or repeater pipets
- Centrifuge, 3000 *g*
- Vortex
- Standard single-use laboratory glass or plastic vials, cups, etc.
- Microtiter plate reader (required filters see chapter 7)

  * Immundiagnostik AG recommends the use of ultrapure Water (Water Type 1; ISO 3696), which is free of undissolved and colloidal ions and organic molecules (free of particles > 0.2 µm) with an electrical conductivity of 0.055 µS/cm at 25 °C (≥ 18.2 MΩ cm).

5. STORAGE AND PREPARATION OF REAGENTS

- To run the assay more than once, ensure that reagents are stored at the conditions stated on the label. **Prepare only the appropriate amount necessary for each run.** The kit can be used up to 4 times within the expiry date stated on the label.

- Reagents with a volume less than **100 µl** should be centrifuged before use to avoid loss of volume.

- **Preparation of the wash buffer:** The **wash buffer concentrate (WASHBUF)** has to be diluted with ultrapure water **1:10** before use (100 ml WASHBUF + 900 ml ultrapure water), mix well. Crystals could occur due to high salt concentration in the concentrate. Before dilution, the crystals have to be redissolved at room temperature or in a water bath at 37 °C. The **WASHBUF** is stable at **2–8 °C** until the expiry date stated on the label. **Wash buffer** (1:10 diluted WASHBUF) can be stored in a closed flask at **2–8 °C for 1 month**.

- The **lyophilised standards (STD)** and **controls (CTRL)** are stable at **2–8 °C** until the expiry date stated on the label. Before use, the STD and CTRL have to be reconstituted with **500 µl of ultrapure water** and mixed by gentle inversion to ensure complete reconstitution. Allow the vial content to dissolve for 10 minutes and then mix thoroughly. **Standards and controls** (reconstituted STD and CTRL) **can be stored at -20 °C for 4 weeks. Avoid repeated thawing and freezing.**

- **Preparation of the conjugate:** Before use, the **conjugate concentrate (CONJ)** has to be diluted **1:101** in **assaybuffer** (100 µl CONJ + 10 ml ASYBUF).

The CONJ is stable at **2–8 °C** until the expiry date stated on the label. **Conjugate** (1:101 diluted CONJ) **is not stable and cannot be stored.**

- All other test reagents are ready-to-use. Test reagents are stable until the expiry date (see label) when stored at **2–8 °C**.

6. STORAGE AND PREPARATION OF SAMPLES

Sample storage

EDTA plasma and serum

Serum and plasma samples can be stored at room temperature for 4 days, at 2–8 °C for 7 days and for 4 weeks at -20 °C. Avoid more than 2 freeze thaw cycles.

Collection and storage of dried blood spots

50 µl whole blood dripped on a dried sample carrier cleared by Immundiagnostik AG are suitable as sample material after complete drying. We recommend DrySpot-ID (catalogue no DZ9020ID or DZ9021ID) as dried blood spot carrier. The moistened cards are stable for 2 weeks at room temperature.

Preparation of samples

EDTA plasma and serum

Pipet **15 µl** of fresh EDTA plasma or serum sample in a 1.5 ml reaction vial, add **885 µl assay buffer** (ASYBUF) and mix well (dilution **1:60)**.

Preparation of the dried blood samples

1.	Label 2- ml polypropylene tubes.
2.	Remove filter from sampling device.
3.	Put filter in a labelled tube.
4.	Add **1500 µl assay buffer** (ASYBUF) per sample, allow sample to stand for **10 min** at room temperature (15–30 °C).
5.	Vortex for **10 s**. The filter will decolourise.
6.	Centrifuge the samples for **5 min** at **3000 *g*** to remove residual filter pieces.

For testing in duplicates, pipet 2 x 100 µl of each prepared sample per well.

7. ASSAY PROCEDURE

Principle of the test

This ELISA is designed for the quantitative determination of nitrotyrosine. The assay utilises the "sandwich" technique.

Standards, controls and prepared samples which are assayed for nitrotyrosine are added into the wells of a micro plate coated with polyclonal goat anti- nitrotyrosine antibody. During the first incubation step, nitrated proteins are bound by the immobilised primary antibody. Then a peroxidase-conjugated polyclonal goat anti-human serum proteins antibody is added into each microtiter well and a "sandwich" of

primary antibody - nitrated protein – peroxidase-conjugate

is formed. Tetramethylbenzidine is used as peroxidase substrate. Finally, an acidic stop solution is added to terminate the reaction. The colour changes from blue to yellow. The intensity of the yellow colour is directly proportional to the concentration of nitrotyrosine. A dose response curve of the absorbance unit (optical density, OD at 450 nm) vs. standard concentration is generated, using the values obtained from the standards.

Test procedure

Bring all **reagents and samples to room temperature** (15–30 °C) and mix well.

Mark the positions of standards/controls/samples on a protocol sheet.

Take as many microtiter strips as needed from the kit. Store unused strips together with the desiccant bag in the closed aluminium packaging at 2–8 °C. Strips are stable until expiry date stated on the label.

We recommend to carry out the tests in duplicate.

1.	**Before use**, wash the wells **5 times** with **250 µl wash buffer**. After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
2.	Add each **100 µl standards/controls/prepared samples** into the respective wells.
3.	Cover the strips and incubate for **1 hour** at room temperature (15–30 °C) on a **horizontal shaker***.
4.	Discard the content of each well and wash **5 times** with **250 µl wash buffer**. After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.

5.	Add **100 µl conjugate** into each well.
6.	Cover plate or strips with foil tightly and incubate for **1 h** at room temperature (15 - 30 °C) on the horizontal shaker.
7.	Discard the content of each well and wash **5 times** with **250 µl wash buffer**. After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
8.	Add **100 µl substrate** (SUB) into each well.
9.	Incubate for **10–20 min**** at room temperature (15–30 °C) in the **dark**.
10.	Add **100 µl stop solution** (STOP) into each well and mix well.
11.	Determine **absorption immediately** with an ELISA reader at **450 nm** against 620 nm (or 690 nm) as a reference. If no reference wavelength is available, read only at 450 nm. If the extinction of the highest standard exceeds the range of the photometer, absorption must be measured immediately at **405 nm** against 620 nm as a reference.

* We recommend shaking the strips at 550 rpm with an orbit of 2 mm.

** The intensity of the colour change is temperature sensitive. We recommend observing the colour change and stopping the reaction upon good differentiation.

8. RESULTS

The following algorithms can be used alternatively to calculate the results. We recommend using the "4 parameter algorithm".

1. 4 parameter algorithm

It is recommended to use a linear ordinate for the optical density and a logarithmic abscissa for the concentration. When using a logarithmic abscissa, the zero standard must be specified with a value less than 1 (e. g. 0.001).

2. Point-to-point calculation

We recommend a linear ordinate for the optical density and a linear abscissa for the concentration.

3. Spline algorithm

We recommend a linear ordinate for the optical density and a linear abscissa for the concentration.

The plausibility of the duplicate values should be examined before the automatic evaluation of the results. If this option is not available with the programme used, the duplicate values should be evaluated manually.

EDTA plasma and serum

The obtained results have to be multiplied by the **dilution factor of 60** to get the actual concentrations.

Dried blood spots

The obtained results have to be multiplied by the **factor of 40** to get the actual concentrations.

In case **another dilution factor** has been used, multiply the obtained result by the dilution factor used.

9. LIMITATIONS

Samples with concentrations above the measurement range can be further diluted and re-assayed. Please consider this higher dilution when calculating the results.

Samples with concentrations lower than the measurement range cannot be clearly quantified.

The upper limit of the measurement range can be calculated as:

highest concentration of the standard curve × sample dilution factor to be used

The lower limit of the measurement range can be calculated as:

LoB × sample dilution factor to be used

LoB see chapter "Performance Characteristics".

10. QUALITY CONTROL

Immundiagnostik AG recommends the use of external controls for internal quality control, if possible.

Control samples should be analysed with each run. Results, generated from the analysis of control samples, should be evaluated for acceptability using appropriate statistical methods. The results for the patient samples may not be valid if within the same assay one or more values of the quality control sample are outside the acceptable limits.

Reference range

Based on Immundiagnostik AG studies of serum samples of apparently healthy persons (n = 78), the following values were estimated:

Min: **264 nM**

Max: **3 311 nM**

Median: **549 nM**

For 95 % of this collective (95 percentile) a nitrotyrosine concentration of

1674 nM and less was obtained.

We recommend each laboratory to establish its own reference range.

11. PERFORMANCE CHARACTERISTICS

Accuracy – Precision

Repeatability (Intra-Assay); n = 24

The repeatability was assessed with 3 serum samples under constant parameters (same operator, measurement system, day and kit lot).

Sample	Mean value [nM]	CV [%]
1	2 267.64	2.8
2	858.84	3.7
3	869.37	5.0

Reproducibility (Inter-Assay); n = 15

The reproducibility was assessed with a serum and a control sample under varying parameters (different operators, measurement systems, days and kit lots).

Sample	Mean value [nM]	CV [%]
1	2 392.57	10.9
2	958.56	13.0
3	930.67	8.8
4	473.97	12.1
5	931.70	12.3

Accuracy – Trueness

The trueness states the closeness of the agreement between the result of a measurement and the true value of the measurand. Therefore, nitrotyrosine spikes with known concentrations were added to 3 serum samples. The results below were obtained without consideration of the sample dilution factor.

Sample [nM]	Spike [nM]	Expected [nM]	Obtained [nM]	Recovery [%]
8.79	11.1	19.89	18.86	94.84
	22.2	30.99	29.46	95.08
	44.4	53.19	52.63	98.95
	66.6	75.39	78.45	104.07
	88.8	97.59	100.33	102.81
	111.1	119.89	124.23	103.62
14.52	11.1	25.62	25.10	97.99
	22.2	36.72	36.22	98.65
	44.4	58.92	59.24	100.54
	66.6	81.12	82.42	101.60
	88.8	103.32	111.69	108.10
	111.1	125.62	137.22	109.23
7.19	11.1	18.29	18.85	103.05
	22.2	29.39	28.14	95.74
	44.4	51.59	49.54	96.03
	66.6	73.79	70.05	94.92
	88.8	95.99	96.96	101.01
	111.1	118.29	113.72	96.13

Analytical sensitivity

The following value has been estimated based on the concentrations of the standard without considering possibly used sample dilution factors.

Limit of blank, LoB 1.437 nM

Linearity

The linearity states the ability of a method to provide results proportional to the concentration of analyte in the test sample within a given range. This was assessed according to CLSI guideline EP06-A with a serial dilution of 4 different serum samples.

For nitrotyrosine in serum and EDTA plasma, the method has been demonstrated to be linear from 11.03 to 116.98 nM based on the standard curve without considering possibly used sample dilution factors, showing a non-linear behaviour of less than ±20 % in this interval.

Sample	Dilution	Expected [nM]	Obtained [nM]	Recovery [%]
1	1:30	88.27	88.27	100.00
	1:60	44.13	37.99	86.09
	1:120	22.07	20.17	91.38
	1:240	11.03	12.33	111.75
2	1:30	62.79	62.79	100.00
	1:60	31.40	31.18	99.31
	1:120	15.70	17.51	111.56
3	1:15	42.66	42.66	100.00
	1:30	21.33	24.44	114.59
4	1:30	116.98	116.98	100.00
	1:60	58.49	49.98	85.45
	1:120	29.25	24.95	85.30
	1:240	14.62	13.75	94.05

12. PRECAUTIONS

- All reagents in the kit package are for *in vitro* diagnostic use only.
- Human materials used in kit components were tested and found to be negative for HIV, Hepatitis B and Hepatitis C. However, for safety reasons, all kit components should be treated as potentially infectious.
- Kit reagents contain sodium azide or ProClin as bactericides. Sodium azide and ProClin are toxic. Substrates for the enzymatic colour reactions are toxic and carcinogenic. Avoid contact with skin or mucous membranes.

- The stop solution consists of diluted sulphuric acid, a strong acid. Although diluted, it still must be handled with care. It can cause burns and should be handled with gloves, eye protection, and appropriate protective clothing. Any spill should be wiped up immediately with copious quantities of water. Do not breath vapour and avoid inhalation.

13. TECHNICAL HINTS

- Do not interchange different lot numbers of any kit component within the same assay. Furthermore we recommend not assembling wells of different microtiter plates for analysis, even if they are of the same batch.
- Control samples should be analysed with each run.
- Reagents should not be used beyond the expiration date stated on kit label.
- Substrate solution should remain colourless until use.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- Avoid foaming when mixing reagents.
- Do not mix plugs and caps from different reagents.
- The assay should always be performed according to the enclosed manual.

14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE

- This assay was produced and distributed according to the IVD guidelines of 98/79/EC.
- The guidelines for medical laboratories should be followed.
- Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from incorrect use.
- Warranty claims and complaints regarding deficiencies must be logged within 14 days after receipt of the product. The product should be send to Immundiagnostik AG along with a written complaint.

15. REFERENCES

1. Peluffo, Gonzalo, and Rafael Radi. 2007. "Biochemistry of Protein Tyrosine Nitration in Cardiovascular Pathology." *Cardiovascular Research* **75** (2) (July 15): 291–302. doi:10.1016/j.cardiores.2007.04.024.
2. Gonsette, R E. 2008. "Neurodegeneration in Multiple Sclerosis: The Role of Oxidative Stress and Excitotoxicity." *Journal of the Neurological Sciences* **274** (1-2) (November 15): 48–53. doi:10.1016/j.jns.2008.06.029.
3. Ischiropoulos, Harry. 2009. "Protein Tyrosine Nitration--an Update." *Archives of Biochemistry and Biophysics* **484** (2) (April 15): 117–21. doi:10.1016/j.abb.2008.10.034.
4. Köse, Fadime Aydın, Meltem Seziş, Fehmi Akçiçek, and Aysun Pabuççuoğlu. 2011. "Oxidative and Nitrosative Stress Markers in Patients on Hemodialysis and Peritoneal Dialysis." *Blood Purification* **32** (3) (January): 202–8. doi:10.1159/000328030.